GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

Gov. Josh Shapiro announced in October GSK’s $800 million project that is expected to create at least 200 new jobs and retain ...

Ministers must treat medicines supplies as a ‘defence’ issue as it faces ‘hostile activity’ over the brewing trade war ...

Ministers must treat medicines supplies as a ‘defence’ issue as it faces ‘hostile activity’ over the brewing trade war ...

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...

Nigeria's second-largest pharmaceutical company, GlaxoSmithKline (GSK), announced its exit from the country, ending its 51-year presence.

and a long-acting beta2 adrenergic agonist is important to GSK as it must replace lost sales from its ageing blockbuster inhaler, Advair/Seretide. The timing is good for GSK, as Advair generics ...

Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow ...

Aspargo Labs, Inc. ("Aspargo Labs" or the "Company"), a specialty pharmaceutical and MedTech company focused on converting ...

6 Antiviral medications can reduce the viral load and ... Medicine Development Leader HBV Program at GSK. “Given this, there is an urgent need for innovative options that can offer lasting ...

Angina Pectoris Drugs Market Size and ForecastThe global angina pectoris drugs market is poised for substantial growth over ...